Application | Comment | Organism |
---|---|---|
medicine | strategy to overcome acquired erlotinib resistance in NSCLC by inhibiting glutaminase activity. Compound 968, an inhibitor of the glutaminase C, when combined with erlotinib potently inhibits the cell proliferation of erlotinib-resistant NSCLC cells HCC827ER and NCI-H1975. The combination of compound 968 and erlotinib decreases glutaminase C and EGFR protein expression and inhibits glutaminase C activity in HCC827ER cells. Compound 968 combined with erlotinib down-regulates the glutamine and glycolysis metabolism in erlotinib-resistant cells | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
compound 968 | i.e. 5-(3-bromo-4-(dimethylamino)phenyl)-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]phenanthridin-4(1H)-one, combined with erlotinib down-regulates the glutamine and glycolysis metabolism in erlotinib-resistant non-small cell lung cancer cells | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HCC-827 cell | - |
Homo sapiens | - |